Recent reports suggest that mosaic-like sequences within the mtr (multiple transferable resistance) efflux pump 19 locus of Neisseria gonorrhoeae likely originating from commensal Neisseria sp. by transformation can increase 20 the ability of gonococci to resist structurally diverse antimicrobials. Thus, acquisition of numerous nucleotide 21 changes within the mtrR gene encoding the transcriptional repressor (MtrR) of the mtrCDE efflux pump-22 encoding operon or overlapping promoter region for both along with those that cause amino acid changes in the 23 MtrD transporter protein were recently reported to decrease gonococcal susceptibility to numerous 24 antimicrobials, including azithromycin (Azi) (Wadsworth et al. 2018. MBio. doi.org/10.1128/mBio.01419-25   18) . We performed detailed genetic and molecular studies to define the mechanistic basis for why such strains 26 can exhibit decreased susceptibility to MtrCDE antimicrobial substrates including Azi. We report that a strong 27 cis-acting transcriptional impact of a single nucleotide change within the -35 hexamer of the mtrCDE promoter 28 as well gain-of-function amino acid changes at the C-terminal region of MtrD can mechanistically account for 29 the decreased antimicrobial susceptibility of gonococci with a mosaic-like mtr locus. 30
INTRODUCTION 39
Neisseria gonorrhoeae is the etiologic agent of the sexually transmitted infection (STI) gonorrhea. 40 [4] MtrCDE efflux pump is of importance during infection due to its ability to export host-derived antimicrobials 67 such as cationic antimicrobial peptides and progesterone (24) . 68
While single site regulatory mutations impacting mtrCDE expression have been extensively studied (14, 69 [19] [20] [21] [22] 29) , increasing evidence suggests that entry and recombination of donor DNA from commensal 70 Neisseria spp. into the mtr locus can result in multiple nucleotide changes that can decrease gonococcal 71 susceptibility to antimicrobials including Azi and Cro. Thus, the presence of mosaic-like sequences within the 72 mtrR region likely resulting from transformation by DNA from N. lactamica or N. meningitidis has been 73 reported in worldwide-isolated gonococcal strains (25- 28, 30) . Recent work by Wadsworth et al. (30) showed 74 that gonococci bearing diverse mosaic-like sequences within the mtrR/mtrCDE promoter region have elevated 75 expression of mtr-associated genes and decreased susceptibility to Azi. Importantly, mosaic-like sequences 76 within the mtrD inner membrane transporter protein-encoding gene showed strong linkage disequilibrium and 77 epistatic effects that likely enhance the activity of the MtrCDE efflux pump (30) . Taken together, the available 78 information strongly suggest that mosaic-like sequences in the mtr locus can result in increased expression of 79 the mtrCDE efflux pump operon as well as providing a gain-of-function property to MtrD that enhances its 80 ability to export antimicrobials. In this study, we examined gonococcal clinical isolates that possess a mosaic-81 like mtr locus similar to other clinical isolates (30) . We describe both a single nucleotide change in the 82 overlapping mtrR/mtrCDE promoters and a likely mechanism for its impact on gene transcription, and amino 83 acid changes in the C-terminal domain of MtrD that were linked to the decreased antimicrobial susceptibility 84 phenotype expressed by gonococci with a mosaic-like mtr locus. 85 [5] RESULTS 87 Importance of the MtrCDE efflux pump in reduced susceptibility to Azi and other antimicrobials 88 in gonococcal clinical isolates bearing a mosaic-like mtr locus. Public health laboratories associated with the 89 Gonococcal Isolate Surveillance Project (GISP) alert the Centers for Disease Control and Prevention (CDC) to 90 N. gonorrhoeae isolates if the Azi minimal inhibitory concentration (MIC) is 2 µg/ml or greater. High-level 91
MICs to Azi (≥ 256 µg/ml [3] ) is typically due to mutations in the four 23S ribosomal RNA (rRNA) genes (31) . 92
However, in recent years it has become apparent that gonococci can display a so-called "less Azi-susceptible" 93 phenotype characterized by MIC values of 2-4 µg/ml (3, 25-30) that does not involve 23S rRNA mutations. 94
This less Azi-susceptible property may help gonococci escape the action of this macrolide during treatment, 95 especially at extra-genital sites of infection (e.g., the pharyngeal mucosa) where the pharmacokinetic properties 96 of antibiotics are not optimal (32). It is therefore important to define how gonococci can develop decreased 97
Azi-susceptibility in the absence of 23S rRNA mutations as this could result in clinical failure of this macrolide 98 during certain infections. 99
In order to study emergence of gonococcal clinical isolates with reduced susceptibility to Azi and to 100 ascertain the contribution, if any, of the MtrCDE efflux pump system to this phenotype, we analyzed eight 101 clinical strains collected in 2014 that expressed a less Azi-susceptible property (MIC of 2 µg/ml); details of 102 these strains are provided in Materials and Methods and Table S1. Whole genome sequencing (WGS) 103 performed on these eight strains and detailed bioinformatic analysis revealed that they lacked known 23S rRNA 104 mutations associated with high levels of Azi resistance (data not presented). The sequence of the genes within 105 the mtr locus of the 8 strains were identical, and they contained multiple nucleotide differences compared to 106 antibiotic-sensitive reference strain FA19; the details of the WGS performed on these and other strains will be 107 presented elsewhere (Soge and McLean, in preparation). Briefly, an alignment of the nucleotide sequence of 108 the entire mtr locus in clinical strain LRRBGS0002 (hereafter termed CDC2), displaying a less Azi-susceptible 109 phenotype with that of FA19 is shown in Fig. S1A . The nucleotide sequence of the mtr locus possessed by 110 strain CDC2 was most dissimilar to FA19 (as well as three other gonococcal strains [MS11, FA1090 and 111
H041]) in the mtrR/mtrCDE promoter region, the mtrD gene and the non-coding region between mtrD and mtrE 112 ( Fig. 1) . A BLAST search against Neisseria (taxid: 482) nucleotide sequences in NCBI (blast.ncbi.nlm.nih.gov) 113 determined that the entire mtr locus sequence possessed by CDC2 was most similar (95% identity) to that of N.
114 polysaccharea M18661 (GenBank: CP031325.1). Analysis of a phylogenetic tree based on the mtr loci of 115 CDC2, FA19, and three clinical strains (GCGS0276, GCGS0402, and GCGS0834) with mosaic-like mtr loci 116 studied by Wadsworth et al. (30) , indicated that at the mtr locus CDC2 was most similar to that possessed by 117 strain GCGS0402 (Fig. S1B ). In fact, the nucleotide sequence of the mtr locus of CDC2 and GCGS0402 was 118 identical. Importantly, however, CDC2 lacked the Correia element (CE) (33) that is positioned adjacent to the 119 mtrR-mtrCDE promoter region found in mtr mosaic-like strain GCGS0276 (30) ( Fig. S1A ). 120 Since CDC2 contained numerous nucleotide sequence variations (with respect to FA19) in the mtrR 121 coding region and the overlapping mtrR/mtrCDE promoter region, we hypothesized that it (as well as the seven 122 other alert strains) might over-produce the MtrCDE pump leading to decreased susceptibility to Azi and other 123 antimicrobials. In order to confirm that this efflux pump is required for antimicrobial resistance in CDC2, as it 124 has been reported for non-mtr mosaic-like clinical isolates such as H041 (29), we created a mutant that lacked a 125 functional MtrCDE efflux pump due to insertional inactivation (mtrD::kan) of the parental mtrD gene, which 126 encodes the MtrD cytoplasmic membrane transporter. We also created other mutants that lacked functional 127 MacAB or NorM efflux pumps to ascertain if their loss might also increase susceptibility of this strain to 128 antimicrobials. Of these three efflux pumps, only loss of an active MtrCDE efflux pump rendered CDC2 and 129 the other Azi alert isolates hyper-susceptible to Azi (Table S1) . Similarly, for CDC2 (Table 1 ) and the other 130 Azi alert strains (data not presented), only the loss of the MtrCDE efflux pump (see CR.99 in Tables S1 and S2) 131 resulted in hyper-susceptibility to the tested antimicrobials.
132 Since the MtrCDE efflux pump was essential for cross-resistance of CDC2 to antimicrobials, we 133 focused on defining the impact of mosaic-like sequences in its mtr locus on MIC values of antimicrobials 134 exported by this pump. For this purpose, we studied expression of the mtrR repressor gene and mtrE gene, 135 which encodes the outer membrane protein (OMP) channel of the pump and is the last gene in the mtrCDE 136
[7] operon ( Fig. 1 and ref. 3). Expression of these genes in FA19 and CDC2 was assessed at the levels of 137 transcription and translation by qRT-PCR and western immunoblotting, respectively. At the level of 138 transcription, it was found that mtrR expression in FA19 was significantly higher than that of CDC2, while 139 mtrE expression was higher in CDC2 ( Figure 2A ). With respect to the MtrR repressor protein, its level in 140 CDC2 and the other seven clinical Azi-alert strains was substantially less than that of strain FA19 ( Figure S2A ). 141 As expected by the low level of the MtrR repressor in CDC2, the level of the MtrE OMP in this strain was 142 higher than that of FA19. In this respect, the level of MtrE in CDC2 was similar to that of strain JF1 143 (FA19ΔmtrR), but less than that of KH15 (FA19 with single bp deletion in the mtrR promoter, which is known 144 to decrease mtrR expression and increase mtrCDE expression ( Fig. S2B ).
145 Increased expression of mtrCDE due to mosaic-like mtrR and mtrR-mtrCDE promoter regions can 146 contribute to, but is not sufficient, for the decreased Azi susceptibility phenotype of CDC2. We 147 hypothesized that the less Azi-susceptible phenotype of CDC2 was due, in part, to enhanced levels of the 148 MtrCDE efflux pump resulting from cis-and/or trans-acting mutations generated by the mosaic-like sequence 149 that influence mtrR and mtrCDE expression. To test this hypothesis, we replaced the FA19 mtrR coding and 150 mtrR-mtrCDE promoter sequences with that possessed by CDC2 and tested if this would influence expression 151 of these genes as well as increasing MICs of Azi and other antimicrobials recognized by the MtrCDE efflux 152 pump. For this purpose, a PCR-generated DNA fragment containing the mtrR coding region, the mtrR-mtrCDE 153 intervening region and the 5́ -end of mtrC present in CDC2 (summarized in Fig. 3A ) was used to transform 154 strain FA19 for increased resistance to a known MtrCDE substrate, triton X-100 (TX-100). A resulting 155 transformant termed CR.100 (Tables 1 and 2) was selected for more detailed studies. DNA sequencing revealed 156 that CR.100 had mtrR coding and mtrR-mtrCDE promoter sequences that contained most, but not all, of the 157 CDC2 donor mosaic-like DNA in this region (Fig. 3A) . With respect to the nucleotide changes in the non-158 coding sequence, CR.100 had the CDC2 mosaic-like sequence that included one nucleotide change within the -159 35 hexamer of the mtrR promoter (C to T) and one change within the -35 hexamer of the mtrCDE promoter (T 160 to G) ( Fig. 3A and Table 2 ) that have been observed in other strains (26, 30) . In this respect, Wadsworth et al 161
found that the -35 mtrR promoter mutation was (present in GCGS0402, while the -35 mtrCDE promoter 162 mutation was present in all three of the mtr mosaic-like strains used in their study (30) . Although a nucleotide 163 difference was also noted in the previously identified transcriptional start site (TSS) for mtrCDE transcription 164 (18) , primer extension analysis revealed that transcription of mtrCDE in strains CDC2 and FA19 was similarly 165 initiated ( Fig. S3 ). CR.100 also contained the CDC2-derived mosaic-like sequence in mtrR, which was 166 characterized by missense mutations in codons 79 (D79N), 183 (S183N) and 197 (M197I) (Fig. 3B) .
167 As is shown in Table 1 , transformant strain CR.100 was more resistant than parent strain FA19 to a 168 panel of MtrCDE substrate antimicrobials, but was two-fold less resistant than donor strain CDC2 to macrolides 169 Azi and Ery and 4-fold less resistant to ethidium bromide (EB). An examination of transcript levels of mtrR 170 and mtrE in FA19 vs. CR.100 showed that mtrR expression was decreased in CR.100 while mtrE expression 171 was increased ( Figure 2B ). Although the MtrR repressor protein was readily detected in whole cell lysates of 172 FA19, it was much lower in transformant strain CR.100 ( Fig. 4 ). This result indicated that acquisition of the 173 mosaic-like sequence encompassing the mtrR coding and mtrR-mtrCDE promoter sequences resulted in 174 transcriptional repression of mtrR and de-repression of mtrCDE. However, it was unclear as to whether these 175 gene expression differences and increased MICs of antimicrobials were due to the mtrR-coding or promoter 176 mutations present in CR.100. 177 In order to separate potential influences of cis-or trans-acting mutations in the overlapping 178 mtrR/mtrCDE promoter regions with that of the mtrR coding region, respectively, on levels of antimicrobial 179 resistance and gene expression in CR.100, we generated a pair of PCR products that singularly covered these 180 regions in CDC2. We found that both regions could transform WT strain FA19 for decreased susceptibility to 181 TX-100 or Azi. Recovered transformants were termed CR.101 and CR.102. DNA sequencing of PCR products 182 from CR.101 and CR.102 was performed to determine the extent of recombination of the donor mosaic-like 183 sequence in the mtrR coding or upstream non-coding region. With the promoter region-bearing PCR product, 184 we found that complete replacement of the wild-type mtrR-mtrCDE intervening region by the donor sequence 185 from CR.100 had occurred in CR.101 (Table 2 and Fig. 3A ). In contrast, with the mtrR coding PCR product, 186
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only the MtrR D79N mutation was present in CR.102; the MtrR amino acid alignment information is provided 187 in Fig. 3B and summarized in Table 2 . Antimicrobial susceptibility testing results (Table 1) showed that the 188 MICs of macrolides against CR.101 (mosaic-like mtrR-mtrCDE intervening region) was two-fold higher than 189 that of CR.102 (MtrR D79N). Interestingly, TX-100 resistance was > 32-fold higher in CR.101 than CR.102 190 (MtrR D79N); the MIC against CR.101 resembled that seen with KH15 (Table 1) which has a single bp deletion 191 in the mtrR promoter that abrogates mtrR gene expression and shifts RNA polymerase recognition to the 192 mtrCDE promoter (15) . In contrast, the TX-100 MIC versus CR.102 was similar to that of JF1 (Table 1) , which 193 has a deletion of mtrR but retains a wild-type mtrR promoter (34) .
194 The results from antimicrobial susceptibility testing suggested that mtrR coding and non-coding mosaic-195 like sequences have different impacts on expression of mtr-associated genes. Indeed, we found that while the 196 MtrR D79N mutation in CR.102, which is also possessed by GCGS0402 and GCGS0834 (30), resulted in 197 increased levels of mtrE expression compared to parental strain FA19 it also, unlike CDC2 and CR.100, had 198 increased levels of the mtrR transcript ( Fig. 2D ) and the MtrR repressor protein (Fig. 4) . Although position 79 199 of MtrR is outside of the DNA-binding domain of this repressor (14, 15), we suggest that this amino acid 200 change causes a decrease in MtrR function resulting in de-repression of mtrCDE expression. Nevertheless, the 201 consequence of this mutation did not endow gonococci with either the antimicrobial resistance profile or the 202 mtrR gene expression profile observed for CDC2 or CR.100 that also have mtrR/mtrCDE promoter mutations 203 (Table 1 and 204 Based on the findings with CR.102, we next tested whether potentially cis-acting mutations in the mtrR-205 mtrCDE promoter region influence expression of mtrR or mtrCDE. As was observed with clinical isolate 206 CDC2 and transformant strain CR.100, the presence of the mosaic-like mtrR-mtrCDE promoter region in 207 CR.101 resulted in a decreased level of mtrR expression, but increased amounts of the mtrE transcript compared 208 to parental strain FA19 (Fig. 2C ). We hypothesize that mutations upstream of mtrR, especially the single 209 nucleotide changes in the adjacent -35 hexamers of the mtrR and mtrCDE promoters (Fig. 3A) , negatively 210 impact expression of mtrR expression. Such repression of mtrR would not occur in CR.102 (MtrR D79N) 211
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where the wild-type FA19 promoter sequence is present ( Fig. 3A) and MtrR levels are elevated ( Fig. 4 ). 212 Coupled with the antimicrobial susceptibility data (Tables 1 and 2) , this result indicated that the nucleotide 213 changes in the promoter region were responsible for modulating expression of mtrR and mtrCDE in clinical 214 isolate CDC2 and transformant strain CR.100. 215 A single nucleotide change in the mosaic-like mtrR/mtrCDE promoter region can impact gene 216 expression. We hypothesized that the T to G change in the -35 hexamer region of the mtrCDE sigma-70 217 promoter in clinical isolate CDC2 and FA19 transformant strains CR.100 and CR.101 (red arrow, Figure 3A ) 218 directly raised mtrCDE expression ( Figure 2A ) and the MICs of MtrCDE antimicrobial substrates (Table 1) ; a 219 similar nucleotide change was observed by others in mtr mosaic-like strains (26, 30) . This nucleotide change 220 would result in an improved -35 hexamer (5´-TTTTAT-3´ to 5´-TTGTAT-3´) of the mtrCDE promoter. To test 221 the importance of this T to G change, two pLES94 mtrCpromoter-lacZ fusion (P mtrC-lacZ ) constructs containing 222 either the CDC2 mtrCDE promoter (CR.102pLES2.2) or an identical sequence but with the T nucleotide 223 (CR.102pLES4.1) were introduced into CR.102 (FA19 MtrR D79N) by transformation; the lacZ fusions 224 integrated in the proAB region of the gonococcal chromosome (35) . After verification of selected transformants 225 by DNA sequencing of PCR products, levels of beta-galactosidase (β-gal) were measured. As is shown in Fig. 226 5, the β-gal expression level was 3.5-fold higher in gonococci with the P mtrC-lacZ fusion that contained the G 227 nucleotide in the -35 sequence of mtrCDE promoter compared to the variant that had the T nucleotide. This 228 result suggests that the T to G change observed in the -35 hexamer of the mtrCDE promoter possessed by 229 CDC2 as well as other isolates (30) results in a more effective mtrCDE promoter than that possessed non-230 mosaic strain FA19. However, since MtrR can activate certain gonococcal genes (34) it was necessary to 231 eliminate the (remote) possibility that the T to G nucleotide change facilitated binding of MtrR D79N to the 232 mtrCDE promoter in an activating capacity. Accordingly, we introduced the P mtrC-lacZ fusion in pLES2.2 into 233 strain JF1 (FA19 ΔmtrR). The results showed that compared to CR.102, expression of P mtrC-lacZ from the 234 pLES2.2 fusion in JF1 was slightly elevated (data not presented), which is consistent with the MtrR D79N 235 [11] protein in CR.102 retaining a degree of transcriptional repressive activity as opposed to becoming an activator 236 of mtrCDE.
237 Mutations in mtrD due to acquisition of a mosaic-like sequence can increase antimicrobial 238 resistance. The results from the gene expression studies described above implicated the T to G change in the -239 35 mtrCDE promoter hexamer as having a strong cis-acting influence that de-represses mtrCDE expression 240 leading to decreased susceptibility of gonococci to antimicrobials, including Azi. Collectively, these findings 241 likely explain the levels of mtrR and mtrCDE gene expression in mtr mosaic-like strain CDC2 and other clinical 242 isolates (26, 30) that possess this mutation. However, these transcriptional changes could not fully explain the 243 higher MIC values of certain antimicrobials against CDC2. Thus, although transformant strain CR.100 had 244 decreased susceptibility to all tested antimicrobials, only the MIC values of crystal violet (CV) and TX-100 245 matched that of CDC2 (Table 1) . We hypothesized that amino acid differences in MtrD efflux pump transporter 246 protein possessed by CDC2 compared to FA19 and CR.100 might account for the higher Azi MIC seen with 247 strain CDC2. Based on the structure of MtrD (PDB 4MTI, ref. 36 ) and known similarity to AcrB (43), the 248 following amino acid changes in MtrD possessed by strain CDC2 are predicted (E. Yu, personal 249 communication) to impact its binding of antimicrobials: T42N, H46R, I48T, N101D, V662I, and K823E. To 250 test whether these or other amino acid changes contribute to antimicrobial resistance in CDC2, three 251 overlapping PCR products (summarized in Fig. S4 ) encompassing its entire mtrD gene were used together to 252 transform strain CR.100 for resistance to 1 µg/ml of Azi. A resulting transformant (CR.103) was examined in 253 antimicrobial susceptibility assays and was found to have identical levels of resistance as CDC2 to Azi (MIC of 254 2 µg/ml) and Ery (MIC of 4 µg/ml,), but was two-fold less resistant than CDC2 to the dye EB (Table 1) . DNA 255 sequencing of mtrD PCR products from CDC2, CR.100 and CR.103 showed that the nucleotide sequence of 256 mtrD in these strains was identical to that of FA19 until codon 738 after which the CDC2 sequence had 257 recombined in CR.103 until codon 1020. This recombination event generated twenty-three amino acid 258 replacements in the C-terminal end of MtrD (Fig. 6) . The amino-acid changes in this C-terminal region of 259 MtrD are located in the DC sub-domain of the docking domain as well as in the PC2 sub-domain of the pore 260 [12] region and transmembrane domains TM8 and TM9 (36) . As assessed by qRT-PCR, CR.100 and CR.103 did 261 not differ in levels of the mtrD transcript (data not presented), indicating that differences in levels of 262 antimicrobial resistance between these strains was linked to structural alterations of MtrD located at the C-263 terminal end.
264 In order to verify that amino acid changes in the C-terminal region of MtrD from CR.103 could increase 265 MIC values of Azi, we prepared an mtrD 3´-end PCR product described above from CR.103 and used it to 266 transform CR.100 with selection for resistance to 1 µg/ml of Azi. Six individual transformants were assessed in 267 antimicrobial susceptibility testing assays using Azi and Ery and all showed an elevated level of resistance to 268 these macrolides comparable to that observed with donor strain CR.103 (data not presented). Differences were 269 detected in the nucleotide sequence of the donated 3´-end of mtrD in the transformants indicating that unique 270 sites of recombination had occurred. Translation of the nucleotide sequence to amino acid sequence showed 271 similar as well as unique amino acid changes in each transformant strain (data not presented). Importantly, 272 however, only two amino acid changes, positioned at 821 (Ser to Ala) and 823 (Lys to Glu), were common in 273 all six transformants. In fact, one transformant (CR.104) had only these two amino acid changes ( Fig. 6 and 274 Table 2 ) compared to recipient strain CR.100. We also sequenced the entire mtr locus (6,793 bp) possessed by 275 strains FA19 and CR.104 and found that except for the nucleotide differences in the mtrR coding, mtrR-mtrCDE 276 intervening region and the mtrD allele of CR.104, the mtr locus in these strains were otherwise identical (data 277 not presented). The MIC values of antimicrobials against CR.104 were identical to that of donor strain CR.103 278 (Table 1) ; the sole exception was with CV for which CR.104 was 2-fold more resistant.
279 DISCUSSION 280
Recombination of commensal neisserial DNA sequences into the chromosome of N. gonorrhoeae and N. 281 meningitidis has been well established (26, 30, (37) (38) (39) . Such horizontal transmission of DNA can endow 282 gonococci or meningococci with decreased susceptibility to antibiotics that target the respective gene product.
283 The best example of the consequence of this genetic exchange event is that of mosaic sequences in the pbp2 284 gene (also known as penA), which encodes the beta-lactam sensitive target, penicillin-binding protein 2 (PBP2) 285 [13] (40). The extensive re-modeling of PBP2 that occurs due to the multiple (up to 60) amino acid changes due to a 286 mosaic pbp2 decreases the acylation rate of penicillin and third generation cephalosporins (cefixime and 287 ceftriaxone) (41) . pbp2 mosaic gonococcal strains also frequently contain cis-acting regulatory mutations that 288 increase expression of the mtrCDE efflux pump operon (reviewed in [3] ). Loss of the MtrCDE efflux pump in 289 chromosomally-mediated penicillin resistant gonococci can result in a return to a penicillin-sensitive phenotype 290 (29, 42) , while a similar loss can result in a 2-4-fold increase in susceptibility to Cro and Azi (29) . Thus, 291 mutations that de-repress mtrCDE expression can work with mosaic pbp2 to decrease gonococcal susceptibility 292 to beta-lactams.
293
The mosaic-like mtrR/mtrCDE promoter region described herein and that reported by Wadsworth et al. 299 hexamer sequence for sigma-70 promoters. Further, since this nucleotide change is also within the 13 bp 300 inverted repeat positioned between the -10 and -35 regions of the mtrR promoter it could alter the ability of this 301 sequence to form a DNA secondary structure with regulatory activity. Thus, the position of this nucleotide 302 change would maintain the spacing between the -10 and -35 hexamers of the mtrR promoter but would reduce 303 the T:A bp repeat from 6 to 4. This reduction in the T:A bp repeat may impact promoter recognition by RNA 304 polymerase, which preferentially shifts its recognition from the mtrR promoter to the mtrCDE promoter that has 305 an improved -35 hexamer sequence. It should also be noted that mtr mosaic-like CDC2 exhibited a low level of 306 mtrR expression possibly due to the nucleotide change in the -35 hexamer of the mtrR promoter ( Figs. 2 and 3) .
307 We hypothesize that this may also contribute to the low levels of MtrR in this and other clinical isolates. 308 Interestingly, when the MtrR D79N mutation from CDC2 was placed into strain FA19, which has a WT mtrR 309
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promoter, levels of MtrR increased significantly (Fig. 4) indicating that this mutation can cause dysregulation of 310 autoregulation of mtrR expression. 311 While the -35 mtrCDE promoter mutation can endow gonococci with increased expression of mtrCDE 312 (Fig. 2) and elevate gonococcal resistance to antimicrobials, it did not account for the Azi MIC observed with 313 clinical isolate CDC2 (Tables 1 and 2) . In this respect, the results presented herein and that of Wadsworth et al.
314 (30) show that amino acid changes in mtrD, which result from importation of commensal neisserial DNA, are 315 also necessary for the less Azi-susceptible phenotype of mtr mosaic-like strains such as CDC2 and GCGS0402. 316 Based on the published MtrD structure (36), many of the amino acid positions in MtrD that are changed in 317 CDC2 versus antibiotic-sensitive strain FA19 could influence drug binding, efflux activity or protein stability.
318 Results from our transformation experiments indicated, however, that amino acid changes in the C-terminal end 319 of MtrD, especially at positions 821 (S821A) and 823 (K823E), are sites for gain-of-function mutations that can 320 contribute to antimicrobial resistance seen in mtr mosaic-like strains. These two amino acids are within the 321 PC2 region of MtrD that is part of the pore domain of this transporter and is located at the outermost region that 322 faces the periplasm. Based on the structural comparison of MtrD with the orthologous AcrB protein (44) , 323 position 823 in MtrD is predicted to be a site for binding antimicrobials (E. Yu, personal communication). 324 Amino acid changes located elsewhere in MtrD could also have a similar impact, as indicated by the higher EB 325 MIC value against CDC2 versus transformant strains CR.103 and CR.104. We note that the S821A and K823E 326 changes are also present in the MtrD protein of the GCGS0402 and GCGS0834 strains studied by Wadsworth et 327 al. (30) ; interestingly, GCGS0276, that also possesses a mosaic-like mtrD, has a K823D change that may have a 328 similar functional impact on MtrD activity as the K823E mutation (30) . 329 Active international and national surveillance systems for determining trends in gonococcal resistance to 330 antibiotics coupled with whole genome sequencing and bioinformatic analyses have been instrumental in 331 detecting gonococci with resistance determinants including those generated by mosaic-like mtr sequences (45-332 49) . The detailed molecular, genetic and phenotypic analyses made possible by these efforts have provided new 333 insights regarding the impact of the gonococcal MtrCDE efflux pump in determining levels of bacterial 334 [15] resistance to clinically important antibiotics. The world-wide distribution of strains with mosaic-like mtr loci 335 indicates that future diagnostic tests for resistance determinants should include functionally important 336 nucleotide changes that were not described in earlier studies (summarized in [13] ). Further, the presence of 337 such gonococcal strains re-emphasizes that genetic exchange between gonococci and commensal Neisseria, 338 which is likely to occur in the pharyngeal cavity, can be a major mechanism by which N. gonorrhoeae develops 339 resistance to antibiotics. Thus, in order to enhance monitoring of antibiotic resistance trends, it would be 340 prudent to routinely sample both genital and extra-genital (especially the oral mucosae) sites for the presence of 341 gonococci in patients suspected of having gonorrhea so as to better detect emergence of antibiotic resistant 342 strains in the community. 343 MATERIALS AND METHODS 344 Gonococcal strains, growth conditions, oligonucleotide primers and determination of susceptibility 345 to antimicrobial agents. The gonococcal strains used in this study are presented in Tables S1 and S2. The 346 clinical strains used in this investigation were kindly provided by Edward Bannister, PhD (Dallas, TX) and the 347 Dallas, TX GISP sentinel site. These strains were provided to CDC without patient identifiers and as such, 348 there was no involvement of human subjects in the research reported herein. For most genetic studies we used 349 antimicrobial-sensitive strain FA19 with an introduced rpsL mutation (FA19 Str R ) that confers high level 350 resistance to streptomycin, but for brevity it is referred to as FA19 throughout the text (Table S2 ). Eight 351 gonococcal clinical strains displaying decreased Azi-susceptibility between 2014 and 2015 were also included 352 in this study (Table S1 ). The details of their WGSs and bioinformatic analysis will be presented elsewhere 353 (Soge and McLean, in preparation). Briefly, the eight strains were selected based on their representation within 354 one of four different clades that were identified by analysis of a generated phylogentic tree from thirty-seven 355 strains. Of these, strain LRRBGS0002 (CDC2 ; Table S2 ) was the most extensively studied. Gonococcal strains 356 were grown overnight at 37 o C under 5 % (v/v) CO 2 on GCB agar containing defined supplements I and II (21) .
357 The sequences of oligonucleotide primers used in this study are shown in Table S2 . The MICs of 358 [16] antimicrobials were determined by the agar dilution method (50) using the GISP protocol (51) . Antimicrobials 359 were purchased from Sigma Chemical Co. (St. Louis, MO).
360 Bioinformatic analyses of WGS information. To compare the sequences of the mtr loci among the strains, 361 sequences for strains FA19, FA1090, and MS11 were retrieved from NCBI genome sequence database 362 (https://www.ncbi.nlm.nih.gov/nuccore/) or NCBI Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra); 363 the H041 WGS sequence was kindly provided by R. Nicholas (University of North Carolina-Chapel Hill, NC). 364 Sequence read files for LRRB strains used in this study (Table S1) 368 the newly assembled sequences in order to recover their mtr locus sequences for alignment. Raw sequence files 369 for GCGS0276, GCGS0402, and GCGS0834 (30) were downloaded from NCBI SRA, and trimmed and 370 assembled according to published methods with cutadapt (52) and SPAdes (53) . NCBI-blast toolkit (BlastN 371 [https://www.blast.ncbi.nlm.nih.gov]) retrieved the sequences for the mtr operon based on FA19 mtr locus 372 sequence. Alignments were performed using the Clustal Omega multiple sequence alignment tool for 373 nucleotide and amino acid sequences (54, 55) , and percent identity values were obtained from the resulting 374 pairwise identity matrix. The Newick file derived from the alignment was visualized using Interactive Tree of 375 Life (iTOL) (56) .
376 Strain constructions. To construct mutants of the eight decreased Azi-susceptible clinical isolates 377 genomic DNA from strains KH14 (FA19mtrD::kan), FA19norM::kan and FA19macA::kan were used in 378 transformation experiments as described previously (21) and verified by PCR using oligonucleotide primer 379 pairs for each gene (Table S3 ). Strains KH14 and FA19norM::kan have been previously described (21, 57) . 380 FA19macA::kan was constructed in this study. Briefly, primers macAF and macAR (Table S2 ) were used to 381 PCR amplify macA from FA19 genomic DNA. The resulting PCR product was cloned into the pBAD-TOPO 382 vector as described by manufacturer (Invitrogen) to create pBADmacA, which was then digested with SmaI. 383 [17] The non-polar kanamycin (Kan) resistance cassette aphA3 (58) was cloned into the SmaI site and the resulting 384 plasmid (pBADmacA::kan) was transformed into FA19. Transformants were selected on GCB agar containing 385 50 g/ml of kan and were verified by PCR. PCR products were generated using CDC2 genomic DNA and 386 primers CEL1 and KH9#12B (to construct CR.100) or primers CEL4 and mtrCpromR (to construct CR.101) or 387 primers CEL1 and KH9#10B (to construct CR.102). The resulting PCR products were transformed into FA19 388 as previously described (18) . CR.100 clones were selected on GC plates supplemented with 3,600 g/ml of TX-389 100. CR.101 was selected on GC plates supplemented with 0.25 g/ml of Azi. CR.102 was selected on GC 390 plates supplemented with 400 g/ml of TX-100. The presence of mutations in the clones was verified by 391 sequencing. For construction of CR.103, PCR products were generated with primers mtrD11Rev and mtrD3, 392 mtrD3Rev and mtrD1, and mtrE12 and mtrD10 using CDC2 genomic DNA as template. The 3 PCR products 393 were used together to transform strain CR.100 using a selection of 1 µg/ml of Azi; a resulting transformant was 394 termed CR.103. For construction of CR.104, a PCR product was generated with primers mtrD10 and mtrE12 395 on genomic DNA from CR.103. The resulting PCR was transformed into CR.100 and clones were selected on 396 GC agar plates supplemented with 1 g/ml of Azi.
397 Quantitative reverse transcriptase-polymerase chain reactions (qRT-PCR). RNA was extracted 398 from strains FA19, CDC2, CR.100, CR.101, CR.102 and CR.104 at mid-logarithmic phase of growth in GC 399 broth plus supplements by the TRIzol method as directed by the manufacturer (Thermo Fisher Scientific, 400 Waltham, MA) and was performed as described (59) . Briefly, genomic DNA (gDNA) was removed by RNAse-401 free DNAse treatment and gDNA Wipeout (Qiagen, Germantown, MD). The resulting RNA was then reverse 402 transcribed to cDNA using the QuantiTect Reverse Transcriptase kit (Qiagen) as described (57). Primers 403 16Smai_qRTF and 16Smai_qRTR were used for 16S rRNA. Primers mtrEqPCR-F and mtrEqPCR-R were used 404 for the mtrE gene, primers mtrD8 And mtrD13 were used for the mtrD gene. Primers mtrR_qRT_F and 405 mtrR_qRT_R were used for the mtrR gene. Sequences of primers are shown on Table S2 . Results were 406 calculated as normalized expression ratios (NER) using 16S rRNA expression levels. Statistical significance 407 was calculated by Student's t-test. 408 [18] Western immunoblot analysis. Whole-cell lysates were prepared from gonococcal strains grown 409 overnight on GC agar plates with supplements as described previously and separated by sodium dodecyl sulfate 410 polyacrylamide gel electrophoresis (SDS-PAGE) (60) . Coomassie brilliant blue (CBB) staining of duplicate 411 SDS-PAGE gels was performed to calibrate and verify consistent loading of proteins (15 µgs) loaded into each 412 well. The concentration of protein in whole cell lysates was estimated by using a Nanodrop spectrometer at 280 413 nM. Western immunoblotting using a mouse anti-MtrE serum (kindly provided by A. Jerse) and a rabbit anti-414 MtrR serum was performed as described previously (23, 34) . 415 β-gal assays. lacZ fusions were constructed using the pLES94 system as previously described (35) . 416 Briefly, PCRs were performed on genomic DNA from strain CDC2 using primers C2 and C3PmtrC for 417 pLES2.2 and C4 and C3PmtrC for pLES4.1. The resulting PCR products were cloned into the BamH1 site of 418 pLES94. pLES94, pLES2.2 and pLES4.1 and were introduced into strains CR.102 or JF1 by transformation 419 with selection on GC agar plates supplemented with 1 µg/ml of chloramphenicol. β-gal assays were performed 420 in triplicate as described by Folster et al. (34) from lysates of gonococcal strains after growth overnight on GC 421 agar plates supplemented with chloramphenicol. The -gal specific activity was calculated using the formula: 422 A 420 x 1000/A 280 (mg/ml) x time (min) x volume (ml).
423 Primer extension analysis. Total RNA from strains FA19 and CDC2 was prepared from mid and late-424 logarithmic phase GCB broth cultures by the TRIzol method as directed by the manufacturer (Thermo Fisher 425 Scientific, Waltham, MA). Primer extension experiments were performed as described previously (18) 1 . Shown are the nucleotide and amino acid sequence percent identities of genes and intervening 619 regions of the mtr locus possessed by gonococcal strains with respect to FA19 (CP012026.1). Accession 620 numbers are provided in Table S1 . Clustal Omega multiple sequence alignments were performed using N. 621 gonorrhoeae strains FA19, CDC2, FA1090, H041, and MS11. Alignments were generated for each mtr gene 622 using their nucleotide and amino acid sequences, and nucleotide sequences were aligned for the intergenic 623 regions. Pairwise identity matrices were calculated, and the pairwise identity values for each alignment are 624 shown. 625 626 Figure 6 . Shown are the sequences of the MtrD protein produced by gonococcal strains as deduced by DNA 659 sequencing. Amino acid differences of MtrD from strains CDC2, CR.100, CR.103 and CR.104 compared to the 660 FA19 are shown in green, with amino acids predicted to be sites for binding antimicrobials shown by red 661 asterisks. 662 663 [33] 
